CPHI Tiesioginiai signalai | Didinkite pelną su Getagraph.com

Live Chart Being Loaded With Signals

Commentary (3 geg. 2024 @ 16:58):

Stats
Šios dienos apimtis	28 160.00
Vidutinė apimtis	427 042
Rinkos kapitalizacija	4.54M
EPS	$0 ( 2024-04-01 )
Kita pelno data	( $0 ) 2024-05-10
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-0.340
ATR14	$0.00500 (1.63%)

Insider Trading

Date	Person	Action	Amount	type
2023-12-28	Liu Tao (chengdu)	Sell	0	Common Stock
2023-09-29	Li Zhilin	Buy	13 757 063	Common Stock
2022-12-30	Deng Ke	Sell	0	Common Stock
2021-09-09	Li Zhilin	Buy	1 760 000	Common Stock
2020-12-23	Li Zhilin	Buy	2 000 000	Common Stock

INSIDER POWER
100.00
Last 33 transactions
Buy: 32 776 034 \| Sell: 18 065 779

Tūris Koreliacija

Ilgas: 0.00 (neutral)

Trumpas: 0.84 (strong)

Signal:(51.967) Same movement expected

China Pharma Holdings Inc Koreliacija

10 Labiausiai teigiamai susiję koreliacijos

10 Labiausiai neigiamai susiję koreliacijos

Ar žinojote?

Koreliacija yra statistinis rodiklis, aprašantis ryšį tarp dviejų kintamųjų. Jis svyruoja nuo -1 iki 1, kur -1 reiškia tobulo neigiamo ryšio koreliaciją (padidėjus vienam kintamajam, sumažėja kitas), 1 reiškia tobulo teigiamo ryšio koreliaciją (padidėjus vienam kintamajam, padidėja ir kitas), o 0 reiškia jokios koreliacijos (tarp kintamųjų nėra jokio ryšio).

Koreliacija gali būti naudojama analizuojant bet kurių dviejų kintamųjų ryšį, ne tik akcijų. Jis dažnai naudojamas finansų, ekonomikos, psichologijos ir kitose srityse.

China Pharma Holdings Inc Koreliacija - Valiuta/Žaliavos

-0.13
( neutral )

-0.07
( neutral )

0.00
( neutral )

0.16
( neutral )

China Pharma Holdings Inc Finansinės ataskaitos

Annual	2023
Pajamos:	$7.01M
Bruto pelnas:	$-504 881 (-7.20 %)
EPS:	$-0.910

FY	2023
Pajamos:	$7.01M
Bruto pelnas:	$-504 881 (-7.20 %)
EPS:	$-0.910

FY	2022
Pajamos:	$8.10M
Bruto pelnas:	$-493 916 (-6.09 %)
EPS:	$-9.72

FY	2021
Pajamos:	$9.64M
Bruto pelnas:	$349 270 (3.62 %)
EPS:	$-0.0700

Financial Reports:

No articles found.

China Pharma Holdings Inc

China Pharma Holdings, Inc. develops, manufactures, and markets generic and branded pharmaceutical, and biochemical products primarily to hospitals and private retailers in the People's Republic of China. The company offers products in the form of dry powder injectables, liquid injectables, tablets, capsules, and cephalosporin oral solutions. Its products include Cerebroprotein Hydroloysate injection to treat memory decline and attention deficit; Gastrodin injection for tiredness, loss of concentration, poor sleep, and traumatic syndromes of the brain; Propylgallate and Ozagrel Sodium to treat cerebral thrombosis, coronary heart disease, and after surgery complications; Alginic Sodium Diester injection for ischemic heart, cerebrovascular, and high lipoprotein blood diseases; Bumetanide injection to treat edema diseases; and Candesartan for hypertension. It also provides Roxithromycin dispersible tablets for pharyngitis and tonsillitis; Cefaclor dispersible tablets for tympanitis, lower respiratory tract infection, urinary tract infections, and skin/skin tissue infection; Cefalexin capsules for acute tonsillitis; Andrographolide for sore throat caused by upper respiratory tract infection; Clarithromycin granules and capsules; and Naproxen Sodium and PseudophedrineHydrochlorida sustained release tablets. In addition, the company offers Hepatocyte growth-promoting factor, Tiopronin, Compound Ammonium Glycyrrhetate S, and Omeparzole for the treatment of digestive diseases. Further, it provides Vitamin B6 injection; Granisetron Hydrochloride injection to treat nausea and vomiting caused by radiotherapy and chemotherapy during the treatment of malignant tumors; Noni Enzyme, a food supplement; sanitizers; and masks. The company offers its products through distributors, as well as through its network of 16 sales offices and approximately 1,000 sales representatives. China Pharma Holdings, Inc. was founded in 1993 and is based in Haikou, the People's Republic of China.